JPRN-UMIN000018484
Recruiting
Phase 2
A phase II study to evaluate the effectiveness of S-1 + Cetuximab for patients with advanced/recurrent colon cancer who cannot undergo intensive therapy - S-1 and Cetuximab Colon Cancer trial ( SACC trial )
HO HOKKAIDO CANCER CENTER Division of Gastroenterology0 sites57 target enrollmentAugust 1, 2015
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- advanced/recurrent colon cancer patients with RAS wild-type tumors who cannot undergo intensive therapy
- Sponsor
- HO HOKKAIDO CANCER CENTER Division of Gastroenterology
- Enrollment
- 57
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) History of severe allergy 2\) Active synchronous or metachronous malignancy 3\) Severe infectious disease 4\) Severe complications (interstitial lung disease or pulmonary fibrosis, heart failure, kidney failure, hepatic failure, uncontrolable diabetes, Jaundice) 5\) Massive pleural effusion or ascites 6\) Wattery diarrhea 7\) Prior treatment of cetuximab or L\-OHP or TS\-1 8\) Patients who is receiving Flucytosine 9\) Symptomatic brain metastasis 10\) Pregnant or lactating women or women of childbearing potential 11\) Severe mental disorders 12\) Systemic administration of steroid 13\) Severe renal failure, or urinary protein (more than 2\+). 14\) Prior radiotherapy for primary and metastases leision. 15\) History of allergy for L\-OHP and other platinating agent 16\) Sensory alteration or paresthesia interfering with function. 17\) Any other cases who are regarded as inadequate for study enrollment by the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin*s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHLlymphoma10025320NL-OMON36830HOVO60
Active, not recruiting
Not Applicable
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation - HOVON 80 NHrelapsed B cell lymphomaMedDRA version: 8.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaEUCTR2006-002141-37-NLHOVON foundation35
Active, not recruiting
Not Applicable
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHLMedDRA version: 14.1Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2006-007083-28-NLHOVON foundation60
Active, not recruiting
Not Applicable
A Pilot Phase II Study for the evaluation of efficacy and tolerability of Gammaidroxybutyrate (ALCOVER) administered by oral route as add on treatmant in patients affected by DYT 11 Myoclonic Dystonia. - NDEUCTR2006-001039-23-ITISTITUTO NEUROLOGICO CARLO BESTA
Active, not recruiting
Phase 1
VAC071: A study to assess efficacy of the ChAd63/MVA PvDBP vaccinesPlasmodium vivax malariaMedDRA version: 20.0Level: LLTClassification code 10047665Term: Vivax malaria (benign tertian)System Organ Class: 100000004862Therapeutic area: Diseases [C] - Parasitic Diseases [C03]EUCTR2019-000643-27-GBniversity of Oxford / Clinical Trials and Research Governance19